Acrongenomics to Present at Leading Global Investor and Partnering Event
Friday February 22, 9:48 am ET
GENEVA, Acrongenomics, Inc. (OTCBB: AGNM) today announced that Mr. Patrick Gontard, Business Development Associate, will be presenting at the Sachs Associates 7th Annual North America Forum for Investing and Partnering in Biotech in Boston.
The Company will be showcasing its innovative portable diagnostic device, built on its BioLED technology platform. This specialised, light weight, readily portable and easy-to-use device is designed to perform complex biological tests at the site where they are most needed. Three high growth medical diagnostics fields have been chosen as the primary targets for BioLED device development, including Kidney function and Cardiovascular Diseases. Mr. Patrick Gontard will be addressing the advantages of ‘lab-on-a-chip’ devices, building on Acrongenomics standing as an expert in the in vitro diagnostics market.
WHEN: Monday February 25th @ 11:45AM (Eastern Time)
WHERE: Fairmont Copley Plaza, Boston
About Sachs Associates
Sachs Associates is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.
More information on the conference is available online: http://www.sachsforum.com/boston08
About Acrongenomics Inc.
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
